EUVIMEDEUVIMED entdecken
CrossrefInfokarte

The emergence of nanocarriers in the management of diseases and disorders

Preeti Khulbe, Deepa Mohan Singh, Anshu Aman, Eknath D. Ahire, Raj K. Keservani

Community Acquired Infection · 2023-04-19 · 10

DOI: 10.54844/cai.2022.0139 ↗
AbstractBibliografische Angaben

Abstract

Drugs can be delivered using oral nanocarriers in controlled, site-specific releases. Target receptors are physically, chemically, and biologically conjugated while administering a specific medicine. Since micro carriers have a 200 nm width, nanomedicine typically refers to objects with that size. Drugs can be delivered by nanocarriers to parts of the body that are inaccessible. Nanocarriers cannot deliver large pharmaceutical dosages due to their small size. Emulsion-based nanocarriers often have poor drug loading and encapsulation, which restricts their potential for therapeutic use. Various therapeutic nanocarriers exist. Ultrabright nanocarriers, polymeric nanocarriers, smart nanocarriers, nanocomposites, protein nanocarriers, nucleic acid-based nanocarriers, carbon nanotubes, and nanobubbles are examples of novel nanocarriers. All of them have successfully treated cancer. This review looks at targeted drug delivery methods and nanocarriers.

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →